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The successful establishment of most viral infections requires productive pro-
liferation of the viral genetic material. Papillomaviruses are similar to other 
small DNA viruses and utilize a small number of virus-encoded proteins in 
addition to numerous cellular factors to replicate their genome. The viral pro-
teins are the clear minority among all of the factors involved in papillomavirus 
replication; however, the virus is extremely adept at manipulating normal cel-
lular processes to achieve the efficient multiplication of its genome.  
The viral and cellular factors involved in the replication of papillomavirus 
DNA (hereafter referred to as papillomavirus replication) have been the subject 
of thorough research. The recruitment of a host cell’s replication proteins to 
facilitate papillomavirus replication by viral replication proteins is well charac-
terized. However, recent research has established that the factors involved in 
cellular DNA damage signaling and repair pathways are also necessary for effi-
cient papillomavirus replication. These findings raise an intriguing possibility 
that papillomaviruses may hijack the host cell’s DNA repair machinery and use 
it as an additional mechanism for replicating the viral genome. The present the-
sis examines two aspects that are connected with the replication of human papil-
lomaviruses (HPVs). First, we study the characteristics and generation of HPV 
DNA that contains several copies of the viral genome (referred to as oligomeric 
genomes for brevity), which appear during the early phases of HPV replication. 
We establish that the oligomeric genomes arise through homologous recombi-
nation and may represent the manifestation of the involvement of cellular DNA 
repair pathways in viral replication. Second, a detailed analysis of replication 
intermediates generated during the early phase of HPV replication indicates that 
two separate replication mechanisms are utilized for the initial replication of 
HPV genomes. We identify one of the mechanisms as bidirectional theta repli-
cation, which is frequently involved in the replication of small circular double-
stranded DNA genomes such as the papillomavirus genome, and has already 
been implicated in the later stages of HPV replication. We suggest that the other 
mechanism is recombination-dependent replication. Collectively, we propose 
that the identification of replication intermediates generated via two separate 
mechanisms is indicative of a dual-mechanism model of papillomavirus repli-
cation.  
The literature analysis provides information on the medical importance of 
HPV infections, an overview of the papillomavirus life cycle, a detailed de-
scription of the papillomavirus replication cycle, and an overview of cellular 
DNA damage response pathways and recombination-dependent replication.  
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2. LITERATURE ANALYSIS 
2.1 Introduction to human papillomaviruses 
Papillomaviruses are DNA viruses that infect the keratinocytes of cutaneous 
and mucosal epithelial tissue of vertebrates. To date, several hundred different 
papillomavirus variants, which are referred to as types, have been identified (1–
3). Because of their clinical importance, scientific research has primarily con-
centrated on HPVs; however, bovine papillomavirus type 1 (BPV1) has served 
as a useful model for the study of papillomavirus infection in humans.   
 
2.1.1 Medical impact of HPV infections 
Papillomavirus infections in general are most commonly either asymptomatic or 
lead to the formation of benign lesions in the infected tissue, and HPV infec-
tions are no exception.  
HPV is widely detected in samples collected from healthy skin and can be 
considered a component of typical skin microbiota (4, 5). HPV types that infect 
the cutaneous epithelium, such as HPV1 and HPV2, cause a variety of clinically 
insignificant benign epithelial growths, such as warts or papillomas. However, 
emerging evidence suggests a link between the infection of certain cutaneous 
HPV types (e.g., HPV5 and HPV8) and the development of non-melanoma skin 
cancer, especially in immunocompromised and immunosuppressed patients 
(reviewed in (6)).  
HPV types that infect the mucosal epithelium have been established as the 
causative agents underlying several epithelial pathological states. Mucosal HPV 
types are considered to be either low risk or high risk based on the propensity of 
the resulting lesions to progress into malignant tumors. Low-risk HPV types 
(e.g., HPV6b and HPV11) mainly cause genital warts (7, 8); however, both 
HPV6b and HPV11 also cause recurrent respiratory papillomatosis (9), a rare 
yet potentially fatal disease. High-risk HPV types (e.g., HPV16, 18, 31 and 45) 
are implicated in the development of cervical (10, 11) and other anogenital can-
cers (12) as well as head and neck cancers (13, 14). The global prevalence of 
HPV infection in the cervix of asymptomatic women has been reported at 
approximately 11–12%, and there is considerable regional variation: the preva-
lence of HPV infection is significantly higher in developing countries than in 
the developed world (15). Less data are available on the prevalence of HPV 
infection among men; however, the prevalence of HPV infection among the 
women and men of the same population has been shown to correlate reasonably 
well (16). Approximately 5% of new cancers occurring worldwide are attribut-
able to HPV (15, 17), and the incidence of HPV-related cancers is higher in 
less-developed regions than in more highly developed regions (15). The intro-
duction of preventive HPV vaccines has led to a decrease in the prevalence of 
HPV infections (18, 19) and cervical lesions (20–23), especially in countries 
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where a national vaccination program has been implemented. However, the 
vaccines currently on the market are only targeted against nine of the most 
common HPV types (HPV6, 11, 16, 18, 31, 33, 45, 52 and 58) (24) and have no 
reported therapeutic effects. Additionally, because of the high cost of the vac-
cines, they are largely unattainable in developing countries. Currently, there are 
no therapeutic procedures or drugs available to treat HPV infections by 
specifically targeting HPV replication.   
 
2.1.2 HPV genome organization and  
a brief introduction to the viral proteins 
HPVs have an approximately 8-kbp circular double-stranded DNA (dsDNA) 
genome that consists of three major regions: the non-coding region, which is 
also referred to as the upstream regulatory region (URR); the early coding region; 




Figure 1. Schematic representation of HPV11 and HPV18 genomes. The open reading 
frames of HPV early proteins are marked with grey arrows, and the open reading frames 
of HPV late proteins are marked with black arrows. Ori denotes the approximate posi-
tion of the origin of replication, and the short E8 open reading frame is marked with a 
grey square.  
 
The non-coding region of HPV genomes contains binding sites for several cel-
lular and viral regulatory proteins (25–27), transcription start sites (28–32) and 
the origin of replication (33–37).  
The early coding region contains open reading frames (ORFs) for the HPV 
proteins E6, E7, E1, E2, E4 and E5.  
The E1 and E2 proteins are the only viral proteins crucial for the initiation of 
HPV replication. The E1 protein is the main HPV replication protein with DNA 
helicase/ATPase activity (38). Functionally, the protein consists of three main 
domains: the N-terminal regulatory domain, the central DNA-binding domain, 
and the C-terminal helicase domain (reviewed in (39)). The E2 protein is the 
main viral transcriptional regulator, and it participates in the initiation of HPV 
genome replication and maintenance of viral genomes in the infected cells. 
HPV genomes encode a full-length E2 protein containing the N-terminal trans-
4
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activation domain and the C-terminal DNA-binding/dimerization domain con-
nected by a linker region; however, HPV genomes also encode several trun-
cated versions of the E2 protein, which serve various regulatory functions. The 
most thoroughly studied truncated version of the E2 protein is the E8E2 protein. 
The E8E2 protein contains amino acids encoded by the short E8 open reading 
frame located within the E1 open reading frame and the C-terminal domain of 
the E2 protein, and it has been shown to be a strong repressor of HPV repli-
cation and transcription (30, 40–42). The E2 protein and its truncated versions 
bind to the HPV genome through specific 12-bp binding sites, which are mainly 
located in the non-coding regulatory region of the viral genome. The structure 
and numerous functions of the E2 protein have been reviewed in (43).  
The E5, E6 and E7 reading frames encode viral oncogenes. There are sig-
nificant differences in the characteristics of the oncoproteins encoded by the 
low-risk and high-risk types of HPV. The high-risk E6 proteins associate with 
and promote the degradation of cellular tumor suppressor p53 (44, 45) among 
other cellular targets (46). The high-risk E7 proteins modulate cell-cycle regu-
lation of the host cell through several cellular proteins (47–49), most notably 
the retinoblastoma family proteins (50). For the high-risk HPV types, the E6 
and E7 protein expression from the full-length viral genome is necessary and 
sufficient for the in vitro transformation of primary human keratinocytes (51). 
The E6 and E7 proteins encoded by low-risk and high-risk HPV types engage 
with similar major cellular targets and processes, although the low-risk E6 and 
E7 proteins bind their targets with lower affinity (45, 52, 53) and are not suffi-
cient for host cell transformation (54, 55).  
The E5 protein is likely a transmembrane protein, although its functions are 
poorly understood. However, BPV1 and HPV16 E5 proteins are known to 
affect the cell surface expression of the epidermal growth factor receptor and 
stimulate cell growth (56–60) and down-regulate the expression of cellular 
proteins involved in antigen presentation at the cell surface (61–64), thus 
contributing to host cell transformation and immune evasion. Sequence analyses 
have revealed that not all HPVs encode the E5 protein and certain HPVs encode 
two E5 proteins (e.g., HPV11); moreover, the HPV types that encode the E5 
protein have increased carcinogenic potential (65, 66).  
The E4 open reading frame is primarily expressed as part of the E1E4 pro-
tein, which is synthesized from a HPV transcript containing the beginning of 
the E1 open reading frame spliced with the E4 open reading frame (67). Despite 
its name, the E1E4 protein is most abundantly expressed during the late phase 
of HPV infection. The main function of the E1E4 protein is likely to disrupt the 
cellular keratin network (68), which may help to facilitate the release of viral 
particles from the host cell.  
The late coding region contains open reading frames for the HPV capsid pro-
teins L1 and L2. The L1 protein is the major capsid protein and assembles into 
capsid-like structures when expressed in cells (69), whereas the L2 minor capsid 
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protein contributes significantly to the efficiency of viral DNA encapsulation 
and the infectivity of viral particles (70). 
 
2.1.3 Overview of HPV infection in stratified epithelia 
HPVs infect the keratinocytes of stratified mucosal and cutaneous epithelia. 
Epithelial keratinocytes undergo a distinct differentiation program that also 
influences the life cycle of papillomaviruses.  
Stratified mucosal and cutaneous epithelium is separated from underlying 
tissue by the basement membrane. The basal layer of keratinocytes located on 
the basement membrane contains epidermal stem cells and their actively pro-
liferating progeny cells, which are referred to as transiently amplifying cells. 
When the daughter cells of transiently amplifying keratinocytes detach from the 
basement membrane, they stop dividing and begin terminal differentiation. As 
the cells move upward, the expression of keratins increases as programmed cell 
death occurs. This process results in the generation of keratin-filled cell husks 
that provide mechanical resistance to the stratified epithelia. The differentiation 
program of keratinocytes has been reviewed in (71, 72).  
The establishment of productive HPV infection is generally expected to 
involve infecting the keratinocytes of the basal layer. Establishing an infection 
has been reported to require the host cell to enter mitosis (73), and in healthy 
epithelium, the only proliferation-competent cells are basal cells. After entry 
into the basal host cell, the HPV genome undergoes transient initial amplifi-
cation followed by the stable maintenance of the viral genome copy number 
(reviewed in (74)). During infection with high-risk HPV types, the expression 
of oncoproteins E6 and E7 from the viral genome promotes active cell division, 
and the number of infected cells grows in situ (reviewed in (75)); however, the 
mechanisms underlying the initial proliferation of cells infected with low-risk 
HPV types are not well understood.  
The detachment of HPV-infected cells from the basement membrane ini-
tiates the onset of the productive phase of the HPV life cycle. In normal epi-
thelium, keratinocytes exit the cell cycle after leaving the basal layer. However, 
the expression of oncoproteins (both low risk and high risk) is sufficient to 
maintain a host cell environment capable of supporting viral replication 
(reviewed in (74, 76)). As the host cell enters its differentiation program, vege-
tative amplification of the viral genome is induced (reviewed in (74)). Fol-
lowing genome amplification, viral capsid proteins are synthesized and viral 
particles are assembled in the upper layers of the epithelium (77, 78). Finally, 
infectious HPV particles are released from the remains of the host cell (79, 80). 






2.2 HPV replication cycle  
The HPV genome replicates in three separate phases: initial transient ampli-
fication replication, stable maintenance replication, and vegetative amplification 
replication.  
 
2.2.1 Initial transient amplification replication 
The initial transient replication of the papillomavirus genome is generally 
believed to occur soon after viral entry into the host cell, although this has not 
yet been studied in vivo. The rapid amplification of viral genomes during the 
early stages of infection is assumed to occur because of the high copy number 
of viral genomes noted in HPV-positive cell lines established from the cervical 
samples of HPV-infected patients. For example, when the W12 cell line was 
established from a low-grade cervical lesion, it carried approximately one 
hundred copies of the episomal HPV16 genome per cell with the viral copy 
number remaining stable over multiple passages (81). Because notable changes 
in the viral copy number are not observed, the replication of HPV16 genomes 
during the cultivation of W12 cells under regular cell culture conditions likely 
represents the stable maintenance replication phase. Because it is highly un-
likely that the precursor cell of the W12 cell line was infected by such a high 
number of HPV viral particles, it is reasonable to assume that the viral genome 
underwent a transient amplification phase prior to the stable maintenance repli-
cation phase.  
 
 
Figure 2. Simplified overview of productive HPV infection in stratified mucosal epi-
thelium. Layers of mucosal epithelia are indicated on the left, and appropriate phases of 
the viral cycle are indicated on the right. See the text for details.  
 HPV-infected cells 
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Under laboratory conditions, the first stage of papillomavirus replication is 
mimicked by transfecting eukaryotic cells capable of supporting papillomavirus 
replication with the full viral genome. However, only a few cell lines are 
capable of supporting papillomavirus replication, and it usually occurs at a low 
efficiency; moreover, replication that occurs shortly after viral entry into the 
cells is the most difficult to analyze. Alternatively, cells can be co-transfected 
with DNA containing the origin of papillomavirus replication and expression 
vectors for the E1 and E2 proteins. Early research into papillomavirus repli-
cation used BPV1 as a model for determining the events underlying the initial 
transient amplification of papillomavirus genomes, whereas contemporary 
research has primarily focused on studying the different HPV types.  
The only viral proteins that are sufficient and required for the initial repli-
cation of BPV1 and HPV genomes are the full-length E1 and E2 proteins (34, 
37, 82–84). The initial transient replication of the HPV genome is initiated at 
the non-coding region of the viral genome, and the complete HPV origin of 
replication contains three E2 protein binding sites (E2BSs) flanking an A/T-rich 
segment containing the E1 binding site (E1BS) (34, 35, 85–89). The origin of 
replication location in the non-coding region (hereafter referred to as the URR 
origin) is marked in Figure 1 as “ori”. The minimal requirements for the 
initiation of HPV replication are either the presence of the A/T-rich segment 
adjoining a single E2BS or the presence of two consecutive E2BSs (33, 35). 
The efficiency of replication initiation is determined by the number of E2 
binding sites (35, 85, 86). Interestingly, the E1 and E2 proteins can support the 
initiation of replication from heterologous papillomavirus origin sequences (37, 
82); however, the URR origin is the only active origin of replication thus far 
identified in the HPV genome. 
The initial amplification replication is initiated when the full-length E1 and 
E2 proteins bind to the origin of replication. The E1 protein binds to the origin 
of papillomavirus replication as a dimer, and the process is facilitated by the 
formation of the E1-E2 protein complex (90–93). The E2 protein is required for 
efficient origin recognition (90, 91, 94, 95); however, the initiation of repli-
cation is absolutely dependent on the presence of the E1 protein (96). Experi-
ments with purified BPV1 E1 and E2 proteins demonstrated that after the E1-E2 
complex binds to the origin of replication, E2 is displaced and the E1-origin 
complex remains (95). Following the displacement of the E2 protein, the E1 
protein forms a double-trimer complex at the origin of replication (97, 98). The 
E1 double-trimer melts the dsDNA at the origin of replication (97, 99, 100), 
after which a double-hexamer E1 complex is formed (97, 100), with each E1 
hexamer encircling a single DNA strand (101). The initiation of papillomavirus 
replication in the presence of the minimal origin sequence (one E1BS and an 






Figure 3. Schematic overview of the E1/E2-dependent initiation of papillomavirus 
replication from a minimal origin of replication sequence consisting of the E1 binding 
site (E1BS) and a single adjoining E2 binding site (E2BS) (adapted from (102)). See the 
text for details.  
 
The E1 hexamer is a DNA helicase/ATPase (103, 104). The E1 protein also 
interacts with cellular DNA polymerase α-primase (91, 105, 106), replication 
protein A (RPA) (107, 108), topoisomerase I (109), and numerous other cellular 
proteins associated with DNA replication (reviewed in (39)). DNA polymerase 
α-primase initiates eukaryotic DNA synthesis and is required for the repeated 
re-initiation of replication during the synthesis of the lagging DNA strand; RPA 
is the most prevalent eukaryotic single-stranded DNA (ssDNA) binding protein; 
and topoisomerase I is a eukaryotic enzyme responsible for relaxing supercoiled 
DNA. In short, the E1 protein recruits cellular replication proteins to the papil-
lomavirus origin of replication, thus initiating the replication of the viral 
genome. Cellular interaction partners of the E2 protein are also required to 
establish efficient HPV replication. Notably, E2 protein must be able to bind 
topoisomerase IIβ binding protein (TopBP1) to establish viral episomes (110). 
TopBP1 is required for the replication of cellular DNA and the rescue of stalled 
replication forks (111–113). 
The replication initiated by the viral E1 and E2 proteins from the URR 
origin is generally presumed to proceed via bidirectional theta replication; 
however, experimental data are not available to either confirm or disprove the 
hypothesis. Determining the mechanism that underlies the initial amplification 
replication should involve an analysis of replication intermediates that arise 
during the initial phase of HPV genomic replication. Cervical samples for HPV-
associated research are usually collected for diagnostic purposes and do not 
contain enough viral genetic material to allow for an analysis of replication 
intermediates, even if the sample is collected from recently infected tissue. 
Alternatively, samples can be collected from HPV-associated cervical lesions, 
which represent a much later phase of viral infection. Low replication efficiency 
has also hindered the analysis of replication intermediates arising during the 
initial amplification of full-length HPV genomes after transfection into 
eukaryotic cell lines.  
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Theta replication is a common replication mechanism for small circular 
dsDNA molecules, such as bacterial plasmids and certain viral genomes (e.g., 
the polyomavirus genome). During bidirectional theta replication, two repli-
cation forks assemble at the origin of replication and progress in the opposite 
direction until eventually converging upon the complete replication of the mole-
cule. The converging of replication forks is followed by the separation of 
daughter molecules. A notable characteristic of theta replication is that it repre-
sents a so-called circle-to-circle type of replication in which the replication of a 
circular molecule generates circular daughter molecules. A schematic overview 




Figure 4. Simplified overview of bidirectional theta replication. Replication is initiated 
at the origin of replication, where two replication forks are assembled. The assembled 
replication forks then progress in opposite directions until they converge upon the 
nearly complete replication. Following the convergence of the replication forks, the 
daughter molecules are separated and the replication process is finalized.  
 
Bidirectional theta replication is associated with the initial amplification of the 
HPV genome mainly because the mechanism has already been implicated in the 
later phases of papillomavirus replication (114–117). Replication of polyoma-
virus SV40, which is considered to be similar to papillomaviruses in many 
aspects, also occurs via bidirectional theta replication (118). 
 
2.2.2 Stable maintenance replication 
The initial amplification of the papillomavirus genomes in the host cell is soon 
replaced by a replication phase during which the viral genome copy number is 
maintained at a near constant level. Several cell lines established from low-
grade cervical lesions, such as HPV16-positive W12 cells and HPV31b-positive 
CIN612 cells (81, 119), represent the stable maintenance replication phase 
when cultivated under regular cell culture conditions. HPV-positive cell lines 
suitable for the analysis of stable maintenance replication can also be created 
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through full-length HPV genome transfection of cell lines capable of supporting 
HPV replication. BPV1 stable maintenance replication has been studied using 
the ID13 cell line created by transforming the mouse fibroblast C127 cell line 
with BPV1 (120).  
Because suitable model systems are available to study stable maintenance 
replication, several aspects of this particular replication phase have been inten-
sively studied. 
Although the initial transient replication of the papillomavirus genome is 
dependent on the availability of the viral replication proteins E1 and E2, the 
stable maintenance replication phase has been shown to proceed in the absence 
of the E1 protein (84, 121–123). However, an analysis of the replication inter-
mediates generated during the stable maintenance replication phase suggests 
that during this phase the origin of replication is the same as that used during 
the initial transient replication phase (the URR origin) (114, 115, 117). The 
initiation of HPV genomic replication from the URR origin is a strictly E1/E2-
dependent process during initial transient replication, thus reducing the 
likelihood that the initiation of replication from the URR origin during stable 
maintenance replication occurs via an E1-independent mechanism. Collectively, 
these data suggest the involvement of two different replication mechanisms in 
the stable maintenance replication of the HPV genome: an E1/E2-dependent 
mechanism initiated at the URR origin and a separate E1-independent 
mechanism utilizing different initiation sequences.  
The E1/E2-dependent stable maintenance replication initiated at the URR 
origin proceeds via bidirectional theta replication (114, 115, 117); however, the 
mechanism underlying the E1-independent replication of HPV genomes has not 
been identified.  
Whether papillomavirus DNA replicates in a strictly controlled once-per-S-
phase mode or a random mode during the maintenance phase has also been the 
subject of thorough research. Determining the mode of replication offers 
insights into the factors controlling replication initiation and, ultimately, the 
mechanism involved in stable maintenance replication. It has been shown that 
HPV genomes are, in principle, inherently capable of both once-per-S-phase 
and random modes of replication during the stable maintenance phase, with the 
choice depending on the level of viral replication proteins in the host cell (124). 
In the presence of high viral replication factor levels, HPV replicates via a ran-
dom-choice mode, whereas in the presence of low viral replication factor levels, 
the once-per-cell-cycle mode is utilized (124). These data suggest a certain 
degree of flexibility in the mode deployed for HPV replication and may reflect 
the previously discussed utilization of two separate replication mechanisms for 
the stable maintenance of the HPV genomes.  
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2.2.2.1 Maintenance of HPV genomes in host cells 
To complete a productive viral life cycle, papillomavirus genomes must be 
maintained in host cells as extrachromosomal molecules. During stable mainte-
nance replication, BPV1 and HPV DNA persist in eukaryotic cell lines as a mix 
of molecules containing a single copy of the viral genome and molecules con-
taining several copies of the viral genome (oligomeric genomes) (114, 115, 125, 
126). The presence of oligomeric HPV genomes has also been detected in HPV-
associated cervical lesions (127–133). However, the mechanism underlying the 
generation of oligomeric HPV genomes and the biological relevance of the viral 
genomic oligomers have not been investigated.  
High-risk HPV DNA can also be maintained in host cells in an integrated 
form. The integration of HPV DNA into the host genome is generally viewed as 
a hallmark of aberrant infection and frequently linked with the potential malig-
nant progression of HPV-associated lesions (134). The E1 and E2-driven repli-
cation of integrated HPV sequences has been proposed as the mechanism 
underlying the genomic instability that potentially facilitates the malignant 
transformation of the host cell (135, 136).  
Because the stable maintenance phase of replication occurs in the actively 
dividing keratinocytes of the basal layer, efficient segregation of extrachromo-
somal papillomavirus genomes between daughter cells is paramount for the 
maintenance of infection. The efficient segregation of papillomavirus genomes 
is achieved by tethering the viral genome to host mitotic chromosomes using 
the E2 protein and E2 binding sites (137–139).   
 
2.2.3 Vegetative amplification replication 
When the host cell detaches from the basement membrane and enters its dif-
ferentiation program, a vegetative amplification of the viral genome is induced. 
The vegetative amplification replication of HPV genomes can be mimicked in 
vitro by cultivating HPV-positive keratinocyte cell lines in high-calcium 
medium, suspended in methylcellulose, or cultivating them as organotypic raft 
cultures. Vegetative amplification has also been analyzed using samples col-
lected from HPV-infected patients. However, determining the exact phase of 
replication in patient samples can be difficult without the opportunity to observe 
possible HPV genome copy number variations over time; therefore, in patient 
samples, the vegetative amplification replication phase may be confused with 
the stable maintenance replication phase.  
The vegetative amplification of HPV genomes depends on the presence of 
the E1 protein (84). Upon entering the vegetative amplification replication 
phase, HPV activates members of the cellular endoprotease protein family 
caspases, which in turn cleave the viral E1 protein from a conserved site located 
in the N-terminal regulatory domain (140). Cleavage of the E1 protein is 
required for the vegetative amplification of the HPV genome (140), although 
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the molecular mechanism underlying this phenomenon remains unknown. 
During host cell differentiation, HPV genomes also activate cellular DNA 
damage response pathways and recruit cellular proteins involved in homologous 
recombination to nuclear viral replication foci, which is a prerequisite for the 
vegetative amplification of HPV genomes (141–143).   
It is generally believed that during the vegetative amplification phase, HPV 
genomes replicate via a different mechanism than during the two previous rep-
lication phases. In W12 and CIN612 cells, the vegetative replication of HPV16 
and HPV31b genomes has been found to proceed via a unidirectional repli-
cation mechanism without specific origin or termination sequences (117). Ini-
tially, the mechanism was suggested to be rolling-circle replication, which is a 
common replication mechanism for several bacterial plasmids and viral ssDNA 
genomes.  
Rolling-circle replication of bacterial plasmids is initiated by the site-
specific generation of a nick at the dsDNA origin of replication, which is 
mediated by specific initiator proteins. The 3’ DNA end generated during the 
nicking process is then extended by a DNA polymerase during leading strand 
synthesis, whereas the cleaved non-template DNA strand is simultaneously 
displaced from the replicating molecule. During the replication of bacterial 
plasmids, the leading strand synthesis usually proceeds until the nicking site is 
reached; subsequently, replication of the leading strand is terminated and the 
displaced strand is released from the replicated molecule. The displaced ssDNA 
then serves as the template for the synthesis of the lagging strand, with repli-
cation initiated from a special ssDNA origin sequence. Rolling-circle repli-
cation of bacterial plasmids has recently been reviewed in (144).  
Alternatively, rolling-circle replication has been suggested to result in the 
generation of circular molecules with concatemeric linear “tails”, such as the 
intermediates of bacteriophage λ late replication (145, 146). This type of 
rolling-circle replication is also referred to as sigma replication. Bacteriophage 
λ late replication intermediates contain more than two copies of the phage 
genome (146–148), indicating that replication of the leading strand is not 
terminated upon reaching the initiation site but proceeds for several rounds. The 
generation of dsDNA linear tails also implies that the synthesis of the lagging 
strand is initiated well before the termination of the leading strand synthesis; 
otherwise, replication intermediates with ssDNA tails would have been 
observed. The sigma replication mode is associated with recombination-
dependent replication (149). A schematic overview of rolling-circle replication 
is presented in Figure 5.  
Rolling-circle replication is a unidirectional mechanism that proceeds via a 
single replication fork similarly to the mechanism involved in the vegetative 
amplification of the HPV16 and HPV31b genomes (117); however, there are 
certain inconsistencies between the intermediates of rolling-circle replication 























































































































HPV16 and HPV31b genomes. Rolling-circle replication of bacterial plasmids 
initiates from a clearly defined origin sequence and requires another specific 
ssDNA origin sequence for the efficient synthesis of the lagging strand, whereas 
HPV vegetative amplification intermediates do not display a preference for a 
specific initiation sequence (117). Furthermore, rolling-circle replication of 
bacterial plasmids proceeds via a ssDNA replication intermediate, which has 
not been reported during analyses of replication intermediates generated during 
the vegetative amplification of the HPV16 and HPV31b genomes (117). The 
sigma type of rolling-circle replication generates highly specific σ-shaped repli-
cation intermediates, which can be easily identified during the analysis of uncut 
replication intermediates; however, uncut replication intermediates have not 
been analyzed along with HPV vegetative replication intermediates (117). 
Therefore, rolling-circle replication may not be the mechanism underlying the 
vegetative amplification of the HPV genome; moreover, because cellular 
homologous recombination proteins are recruited to HPV replication centers, 
recombination-dependent replication has recently been proposed as the alter-
native mechanism (142, 143, 150).  
An analysis of the low-risk HPV type 11 replication intermediates isolated 
from vocal cord papillomas suggests that bidirectional theta replication can also 
be involved in the vegetative amplification replication of HPV genomes (116). 
However, it must be noted that the vocal cord papilloma tissue was presumed to 
represent vegetative amplification replication because of its high viral genome 
copy number, which was comparable with copy number of the HPV16 genome 
in the W12-E cell line used as a model for the stable maintenance replication 
(116, 117).  
 
 
2.3 Overview of the cellular DNA damage  
response pathways 
Maintaining a fully functional genome is of the utmost importance for all cells. 
In eukaryotic cells, several mechanisms have developed for the detection and 
repair of DNA lesions, and they collectively form the cellular DNA damage 
response (DDR) mechanism. The DDR utilizes two major signaling pathways 
whose key components are the ATM (ataxia-telangiectasia mutated) and ATR 
(ATM- and Rad3-related) protein kinases. The most notable downstream target 
of ATM is checkpoint kinase 2 (Chk2) (151), which induces cell cycle arrest in 
response to DNA damage (152, 153). The effector of the ATR pathway is 
checkpoint kinase 1 (Chk1), which is similar to Chk2 in that it mediates cell 
cycle arrest in the presence of DNA lesions (154–157). However, the processes 
associated with the activation of the ATM and ATR signaling pathways and 
implementation of the DDR machinery are not completely understood.  
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2.3.1 ATM signaling pathway 
ATM is primarily implicated in the response to DNA double-stranded breaks 
(DSBs). DSBs can be repaired via two principal mechanisms: homologous 
recombination (HR) and non-homologous end-joining (NHEJ).  
HR repairs DNA lesions using a homologous sequence as a repair template 
and regenerates an intact (previously disrupted) sequence. The HR pathway is 
restricted to the S and G2 phases of the cell cycle when homologous molecules 
are present and available as templates, and it is initiated by the detection of 
DSBs by the Mre11-Rad50-Nbs1 (MRN) complex. Mre11 is a nuclease with 
both endonuclease and exonuclease activity (158), and it is crucial to HR 
licensing because Mre11 endonuclease activity is involved in resectioning the 
DSB DNA ends, which is required to initiate the HR pathway (159, 160). 
Rad50 provides a protein scaffold that bridges the DSB ends and maintains the 
proximity of the disjointed DNA ends to each other (161, 162), and Nbs1 is 
required for the activation of ATM kinase (163). The free 3’ ssDNA strands 
generated via Mre11 resectioning invade a homologous molecule in a reaction 
mediated by a distinct set of proteins (e.g., Rad51), thus creating the dis-
placement loop (D-loop) structure. Subsequent to the D-loop creation the syn-
thesis of the missing sequences is initiated. HR has been reviewed in (164), and 
a simplified overview of HR is presented in Figure 6.  
NHEJ is an error-prone mechanism that repairs DSBs by simply joining two 
DNA ends together, which leads to the generation of deletions in the repaired 
DNA sequence and potential rearrangements of genomic material. NHEJ can 
occur throughout the cell cycle and is initiated when DSBs are detected by the 
Ku70/Ku80 heterodimer (reviewed in (165)). A simplified overview of NHEJ is 




Figure 6. Simplified overview of the different pathways utilized to repair dsDNA 





It has been suggested that during the late S/G2 cell cycle phase when DSB 
repair can proceed via both the NHEJ and HR pathways, the Ku70/Ku80 
heterodimer initially binds to DSBs and then NHEJ makes the first attempt at 
repair; if the NHEJ pathway cannot proceed rapidly, then the HR repair path-
way is utilized (166). The distinct nuclease activities of Mre11 are important for 
determining the DSB repair pathway, and Mre11-mediated resectioning of 
DNA ends is crucial for HR pathway licensing and NHEJ repression (159, 160). 
The choice between the HR and NHEJ pathways also appears to be regulated by 
factors involved in more general cellular processes. For example, 
phosphorylation of Nbs1 by the cell cycle progression regulator cyclin-
dependent kinase during the S, G2 and M phases of the cell cycle facilitates the 
MRN-dependent resectioning of DSB DNA ends to promote HR and suppress 
NHEJ (167).  
The HR pathway is directly connected to ATM activation through Nbs1 
(163, 168). However, it must be noted that the MRN complex is also involved 
in DNA damage repair mediated by the ATR signaling pathway (169), and the 
Nsb1 protein is both an upstream regulator and a downstream substrate of ATR 
kinase (170). Furthermore, the essential function of the MRN complex has been 
suggested to be the resolution of replication intermediates rather than the repair 
of DNA lesions (171).  
The connections between the NHEJ pathway and ATM activation are not 
well understood, although several components of the NHEJ pathway have been 
identified as downstream components of ATM signaling (160, 172, 173). 
DSBs can also be repaired via alternative pathways that share similarities 
with both the HR and NHEJ pathways, such as the microhomology-mediated 
end-joining (MMEJ) pathway. The MMEJ pathway relies on short sequence 
homologies (5–25 bp) for the ligation of DNA ends generated via DSBs and 
can, in principle, lead to the accurate repair of DNA molecules in the presence 
of fully complementary ssDNA ends. However, complementary ssDNA ends 
must frequently be generated prior to annealing in a manner similar to DSB end 
processing that leads to the initiation of HR (174). After suitable ssDNA ends 
are generated, the two DNA molecules are ligated, and small deletions usually 
occur in the repaired molecule. A simplified overview of MMEJ is presented in 
Figure 6, and MMEJ has been reviewed in (175). 
 
2.3.2 ATR signaling pathway  
The ATR signaling pathway responds to DNA breaks, adducts and crosslinks 
and replicative polymerase inhibition or stalling (176). ATR is activated by the 
presence of structures containing ssDNA and ssDNA-dsDNA junctions (177–
179). ssDNA is bound by RPA, which is required for the recruitment of ATR 
via an association with ATR-interacting protein (ATRIP) (180). The ATRIP-
ATR complex is then activated by the Rad checkpoint proteins (e.g., Rad9-
Rad1-Hus1 complex) and topoisomerase IIβ-binding protein 1 (TopBP1) (113, 
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181). Alternatively, ssDNA/dsDNA junctions can be directly recognized by the 
Rad checkpoint proteins (182), which then activate ATR signaling via TopBP1 
(183, 184).  
The MRN complex is central to the ATM-mediated repair of DSBs via HR; 
however, it is also involved in the ATR signaling pathway. The MRN complex 
is likely required for ATR activation in response to stalled or collapsed repli-
cation forks and facilitates the ATR-mediated repair of replication-associated 
DSBs (169, 185).  
 
2.3.3 Recombination-dependent DNA replication 
Recombination-dependent DNA replication (RDR) was first demonstrated as 
essential for the late replication of bacteriophage T4 (186, 187), where RDR 
provides a mechanism for replicating the linear ends of the viral genome. RDR 
has also been studied in the bacterium E. coli and budding yeast S. cerevisiae, 
where it is usually referred to as break-induced replication (BIR). The primary 
role of RDR in E. coli has been suggested to be the rescue of collapsed repli-
cation forks (reviewed in (188)). In eukaryotic cells, RDR has been associated 
with an alternative maintenance pathway for chromosome ends (189), and it has 
also been suggested to be essential for the rescue of collapsed replication forks 
(190). 
The initiation of RDR is similar to the initiation of DSB repair via HR, and 
there is considerable overlap among the factors involved in the two processes. 
RDR can be initiated in the presence of both DSBs and ssDNA regions, 
although the crucial prerequisite for the initiation of RDR is the generation of 
free 3’ ssDNA ends, which is mediated by Mre11 nuclease in eukaryotic cells 
(159, 160, 167). The resectioned ssDNA ends subsequently invade a homolo-
gous dsDNA molecule in a reaction mediated by a distinct set of proteins, 
including the Rad51 protein, to create the D-loop structure. The D-loop serves 
as a substrate for recruiting the replicative complex. Although the repair of 
DSBs via HR only leads to the synthesis of the minimum DNA required to 
replace missing sequences, the initiation of RDR leads to the replication of 
extensive DNA sequences well beyond the site of the lesion. BIR has been 
reviewed in (191).  
In bacteriophage T4 and E. coli, RDR has been shown to lead to the 
assembly of a fully functional replication fork and the establishment of semi-
conservative replication (192–195). In S. cerevisiae, BIR requires most of the 
replication factors associated with regular origin-dependent replication (196), 
although Pol32, an otherwise non-essential subunit of DNA polymerase delta, is 
the exception (189); however, in budding yeast, BIR leads to error-prone con-
servative replication that proceeds along with the migrating bubble (197, 198). 





Figure 7. Simplified overview of recombination-dependent replication (RDR). See the 
text for details.  
 
A distinctive error-prone BIR mechanism, microhomology-mediated break-
induced replication (MMBIR), may be able to initiate via sequence microho-
mologies. MMBIR is likely similar to microhomology-mediated end-joining 
(MMEJ) (199), which is initiated by a limited resectioning of DNA ends by 
Mre11 (174) but is independent of Rad51 (200). The Rad51 protein is otherwise 
essential for eukaryotic RDR (201). MMEJ frequency has been shown to 
increase when cells enter the S phase, and it has been suggested that MMEJ is 
used to repair collapsed replication forks (174). Similarly, the collapse of 
replication forks in stressed cells has been suggested to lead to the initiation of 
MMBIR (199). MMBIR may be the mechanism underlying the creation of copy 
number variations in the human genome (199).  
The involvement of RDR in the late replication of the linear genome of the 
bacteriophage T4 is well known; however, RDR is also involved in the repli-
cation of the bacteriophage SPP1 genome (reviewed in (202)). The SPP1 repli-
cation cycle is characterized by a distinctive switching between circular and 
linear genomic forms. At the onset of infection, the linear dsDNA SPP1 genome 
converts into a circular molecule upon entering the host cell. The circular viral 
genome initially undergoes several rounds of circle-to-circle theta replication, 
although the mode of replication quickly switches to the sigma type of repli-
cation via recombination-dependent restart of collapsed theta replication forks. 
The recombination-mediated sigma replication leads to the generation of linear 
concatemeric SPP1 genomes, which are recognized by the viral DNA 
packaging machinery and processed into mature linear viral genomes packaged 
into progeny viral particles. Although bacteriophage SPP1 is considered the 
primary example of this particular mode of replication, the same mechanism 
may be involved in the replication of bacteriophage λ and herpes simplex virus 
type 1 genomes (149), both of which also utilize the distinct linear-circular-
linear genome conversion and generate linear concatemeric viral genomes 
during infection. The rolling-circle mechanism of bacteriophage λ late 
replication was previously discussed in chapter 2.3.3.  
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2.4 Association of HPV replication and cellular DDR 
The links between HPV replication and cellular DDR components have been 
established for all three phases of papillomavirus replication.  
 
2.4.1 Activation of cellular DDR pathways during initial  
HPV amplification 
The E1 protein, which is required for both the initial and vegetative HPV ampli-
fication replication phases (84), has the intrinsic ability to activate the ATM-
Chk2 signaling pathway and induce cell cycle arrest (203–205). Both the 
ATPase and DNA melting activities of the E1 protein are necessary for DDR 
activation, which is likely the result of E1-generated DSBs (204, 205). E1/E2-
dependent HPV replication is insensitive to DSB-generated replication arrest 
mediated by DDR signaling (206); however, the presence of the E2 protein and 
the viral origin of replication decrease E1-dependent DDR activation during the 
initial amplification phase to the extent that large-scale damage to cellular DNA 
cannot be observed in their presence (203, 204). Furthermore, because 
inhibition of the ATM pathway does not eliminate the transient replication of 
the viral origin in the presence of the E1 and E2 proteins (203) or the initial 
amplification of the HPV genome (204), activation of the ATM-Chk2 pathway 
is likely unnecessary for an efficient initial amplification replication phase, 
although this does not necessarily indicate a general lack of involvement of 
DDR activation in HPV initial amplification. Notably, members of the ATR 
signaling pathway, the ATRIP and TopBP1 proteins, co-localize with HPV 
replication foci during the initial amplification of the viral genome, indicating a 
role for ATR activation in HPV replication (204). Moreover, TopBP1 is a 
known interaction partner of E2, and E2-TopBP1 binding is necessary for the 
establishment of HPV episomes (110).  
 
2.4.2 Stable maintenance replication and cellular DDR 
Several DDR and HR proteins (e.g., activated ATM and Chk2 proteins, RPA, 
Rad51, Mre11 and Rad50) co-localize with HPV replication centers during the 
stable maintenance replication phase; however, this co-localization only occurs 
in a fraction (approximately 50%) of HPV-positive cells (142, 143). Further-
more, the inhibition of DDR does not affect the efficiency of stable mainte-
nance replication (141, 143).  
 
2.4.3 Engagement of cellular DDR for the efficient vegetative 
amplification of the HPV genome 
During the vegetative amplification replication phase, the co-localization of 
HPV replication centers and cellular DDR and HR proteins (e.g., RPA, Mre11, 
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Rad50 and Rad51) is significantly increased, and productive vegetative repli-
cation requires the activation of cellular DDR pathways (141–143). Notably, 
efficient vegetative amplification replication requires Mre11 protein nuclease 
activity and Nbs1-dependent localization of the MRN complex and Rad51 to 
the HPV genome (143). Mre11 protein nuclease activity, the MRN complex and 
the Rad51 protein are the essential requirements of both HR and RDR, and 
these data indicate a role for HR in the vegetative amplification of the HPV 
genome. However, it is important to note that inhibiting the components of HR 
does not eliminate the vegetative amplification replication altogether, sug-
gesting that while HR may be important for HPV DNA replication, it is not 
indispensable.  
Inhibiting the ATM-Chk2 pathway has been shown to disrupt the formation 
of HPV replication foci during vegetative amplification replication and decrease 
the efficiency of viral replication (141). However, fluctuations in the levels of 
activated ATM and Chk2 have not been shown to significantly affect the effi-
ciency of vegetative amplification replication (143). Similarly, although the 
efficiency of the vegetative amplification replication phase depends on Nbs1-
mediated recruitment of the MRN complex and Rad51 to the viral genome, 
Nbs1 depletion does not significantly affect ATM activation (143). The role of 
the ATM-Chk2 pathway in vegetative amplification replication is therefore 
controversial, and ATM activation may serve functions unrelated to the acti-
vation of HR machinery. For example, Chk2 activation during host cell dif-
ferentiation leads to the activation of caspases required for the cleavage of the 
viral E1 protein involved in vegetative amplification (140, 141). Therefore, it is 
likely that HPV deploys different components of the cellular DDR pathways for 
separate albeit partially overlapping functions. Additionally, the uncoupling of 
ATM activation and the recruitment of the MRN complex to viral replication foci 
may indicate that the ATR pathway is engaged during the vegetative ampli-
fication phase of HPV replication, which would mirror the potential involvement 
of the ATR pathway during the initial amplification of the viral genome (204). 
 
2.4.4 NHEJ and HPV replication 
Components of the NHEJ DSB repair pathway have not been shown to localize 
to HPV replication foci (142), which indicates that the components of the NHEJ 
pathway are not involved in or required for HPV replication. Excluding the 
NHEJ pathway components from the HPV replication foci may simply be a 
result of the timing of viral replication with HPV replication shown to occur 
during the S and G2 phases of the cell cycle (207, 208); however, the HR is the 
pathway of choice for the repair of any detected DSBs during these phases of 
the cell cycle (167). Because the involvement of the NHEJ pathway during 
DSB repair has the potential to generate rearranged genomic sequences, 
excluding the NHEJ components from the viral replication centers is most 
likely beneficial for the replication of HPV genomes.   
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2.4.5 HR and HPV integration 
In premalignant and malignant cervical lesions, high-risk HPV genomic mate-
rial is often integrated into cellular DNA. In the case of HPV18, this integration 
appears to be a crucial step in the progression of malignant lesions (134); how-
ever, in the case of HPV16, the viral genome is often present in episomal or 
mixed episomal/integrated forms in tumor biopsies (134, 209). The genomes of 
low-risk HPV types are not generally believed to integrate into cellular DNA.  
Based on the analysis of HPV16, the integration breakpoints in the viral 
genome occur in any part of the viral genome (210, 211), and a preference for 
the often-cited E2 open reading frame is not observed (211). However, data 
suggest that cellular genomic elements related to genomic instability (such as 
copy number variations, genomic rearrangements and common fragile sites) are 
enriched for integrated HPV sequences (210–212). In addition, a noticeable 
enrichment of microhomologies was observed between the cellular DNA and 
HPV genomes at or close to the integration loci (211). Several cellular genomic 
elements related to genomic instability have been associated with recombi-
nation events (reviewed in (213, 214)), and these results suggest a recombi-
nation-associated model of HPV integration (211). Similarly, integrated HPV 
sequences have been shown to recruit several cellular factors associated with 
HR and DDR (136). 
 
2.4.6 Possible implications of DDR activation during  
HPV replication  
The viral functions or factors responsible for activating DDR in HPV-positive 
cells are as yet unknown. Viral oncoprotein E7 expression from expression 
vectors has been shown to increase the activation of Chk2 (141, 143) as well as 
the level of the Mre11, Rad50 and Nbs1 proteins (143). However, full-length 
HPV18 genomes defective for E6 or E7 protein expression were still capable of 
inducing DDR in U2OS cells, suggesting that viral replication alone is suffi-
cient for DDR activation (204).  
Although the collective data clearly indicate that cellular DDR activation is 
required during HPV replication, the exact function of this activation remains 
unknown. The localization of DDR components to HPV replication foci has 
been suggested as indicative of the involvement of RDR in HPV (vegetative) 
amplification replication (142, 143, 150); however, definitive proof has not 
been established to support this hypothesis, particularly considering that DDR 
activation during DNA replication is expected. Because the ATM-mediated 
activation pathway appears to be dispensable for activating DDR during the 
early and late amplification phases of viral replication (143, 203, 204), ATR-
mediated activation can reasonably be expected to be involved in the process, 
especially because components of the ATR pathway have been shown to 
localize to HPV replication centers during the initial viral amplification (204). 
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The recruitment of several factors required for the initiation of both HR and 
RDR to the viral replication centers is an essential pre-requirement for efficient 
vegetative amplification of the HPV genome (143). ATR activation and HR 
functions overlap during the rescue of collapsed replication forks (169, 185); 
therefore, it is plausible that DDR activation during HPV replication merely 
facilitates the repair of replication-associated DNA lesions. Alternatively, 
because the essential role of the MRN complex may be the resolution of repli-
cation intermediates (171), the activation of DDR may be required for the sepa-
ration of newly replicated viral genomes.  
Indications of the involvement of recombination events in the integration of 
HPV into cellular DNA (211) provide additional evidence of a possible link 
between HPV replication and cellular HR machinery. These data indicate that 
HPV replication generates intermediates that are actively recognized and pro-
cessed by the cellular repair machinery. Microhomologies are enriched between 
cellular DNA and the HPV genome close to the viral integration loci (211), and 
these data more specifically implicate the engagement of microhomology-
mediated repair mechanisms during HPV replication.  
 
 
2.5 Brief overview of polyomavirus replication 
The complexity of the papillomavirus life cycle has hindered the study of many 
features of HPV infection, including the exact mechanism of viral replication. 
Research into HPV replication would greatly benefit from the availability of a 
comparable well-studied replication system, and polyomavirus replication has 
been suggested to provide such an analogous model.  
Polyomaviruses are small tumorigenic viruses that have an approximately 
5.2-kbp dsDNA genome and typically establish asymptomatic persistent infec-
tions. In immunosuppressed patients, however, polyomavirus infection may 
lead to the development of severe pathologies (including tumors) (reviewed in 
(215)). Therefore, polyomavirus infections share considerable similarities with 
papillomavirus infections.  
The overall genome organization of polyomaviruses and papillomaviruses is 
also similar, with both viral genomes containing a non-coding regulatory 
region, an early region, and a late region coding the capsid proteins. However, 
notable sequence similarities are not observed between the two groups of 
viruses. The only exception is an approximately 200 amino acid region located 
in the C-terminus of the papillomavirus E1 protein and the polyomavirus large 
T antigen (216). Similar to papillomavirus E1 protein, the large T antigen is the 
primary viral replication protein, and the C-terminal domain of both the E1 
protein and the large T antigen is the helicase domain.  
Polyomavirus genome replication shares several similarities with papilloma-
virus genome replication. Polyomaviruses require a number of host factors to 
replicate their genome, although the initiation of viral replication relies on the 
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assembly of the hexameric large T antigen helicase at the viral origin of repli-
cation. The assembly of hexameric helicases leads to the formation of two repli-
cation forks that replicate the viral genome via bidirectional theta replication. 
The initiation of polyomavirus replication and the functions of the large T anti-
gen are reviewed in (217, 218). The bidirectional progression of polyomavirus 
replication forks is halted when replication is approximately 91% complete and 
occurs in preparation for the separation of daughter molecules (219, 220). The 
separation of daughter molecules appears to be a slow, rate-limiting process, 
with the nearly fully replicated molecules accumulating in polyomavirus-
infected cells (219–221).  
Polyomaviruses actively engage components of the ATM and ATR signaling 
pathways to viral replication foci (222–224) and inhibition of the ATM and 
ATR pathways decreases viral replication efficiency (223–228). An analysis of 
polyomavirus replication intermediates suggests that ATM and ATR are acti-
vated by replication stress and contribute to the maintenance of replication fork 
integrity during replication (222, 224). Additionally, the ATR pathway may 
participate in the separation of daughter molecules following the replication of 
the viral genome (224), while ATM activation represses NHEJ to prevent the 
creation of aberrant viral genomes during replication (229).  
Interestingly, compared with HPV E1/E2-dependent replication, polyoma-
virus SV40 large-T-dependent DNA replication is arrested after the ATR-





3. OBJECTIVES OF STUDY 
Persistent papillomavirus infection is a considerable health risk that could 
potentially lead to the development of severe malignancies. However, the 
development of efficient and specific drugs against papillomavirus infections 
has been hampered by a lack of understanding of viral genome replication and 
maintenance in host cells. Our research group has long concentrated on identi-
fying the mechanisms underlying these viral functions that are essential for the 
establishment of a productive and persistent papillomavirus infection.  
The general objectives of the research detailed in the present thesis involve 
developing a cellular assay capable of supporting all three phases of papilloma-
virus replication and utilizing the developed cellular assay to investigate the 
initial amplification replication of the HPV genome.  
The newly developed U2OS cell line-based model system was implemented 
to study the early events of HPV replication, and we specifically concentrated 
on the following: 
• Examining and characterizing HPV DNA that contains several copies of the 
viral genome (referred to as oligomeric HPV genomes for brevity) generated 
during the initial amplification of HPV type 18 and type 11 genomes; 
• Identifying the mechanisms underlying the generation of oligomeric HPV18 
and HPV11 genomes; 
• Analyzing the replication intermediates generated during the initial amplifi-
cation replication of the HPV18 genome to identify the mechanism of repli-





4. MATERIALS AND METHODS 
In the present thesis, we used the U2OS cell line-based assay system to study 
the characteristics and generation of oligomeric HPV genomes and to analyze 
replication intermediates generated during the initial amplification of HPV 
genomes. The development of the U2OS-based assay has been thoroughly 
described in the Materials and Methods section of paper I.  
Most of the experiments discussed in the present thesis study events that 
occur during the initial amplification of HPV genomes, which was mimicked by 
transfecting the U2OS cells with plasmids containing HPV genomes. Initially, 
input HPV genomes were produced in bacteria as plasmids containing the full-
length viral genome cloned into a bacterial vector. Prior to transfection, HPV 
genomes were cleaved out from bacterial vectors and recircularized at low DNA 
concentrations. The experimental procedures used to generate recircularized 
HPV genomes have been detailed in the Materials and Methods section of paper 
I. Prior to studying the characteristics and generation of oligomeric genomes, 
the production of input HPV genomes for the U2OS cell line-based assay 
system was modified. HPV11 and HPV18 full-length genomes that are 
essentially free from bacterial vector sequences were purified from E. coli strain 
ZYCY10P3S2T as covalently closed circular plasmids generated through mini-
circle production technology (230). The modified U2OS-based assay system 
was also used in paper III. The production of minicircle HPV genomes has been 
detailed in the Materials and Methods sections of papers II and III.  
During the transient replication assay mimicking initial amplification repli-
cation, low-molecular weight (LMW) DNA containing viral DNA was 
extracted from HPV-transfected cells, and the intermediates and end products of 
viral replication were analyzed using agarose gel electrophoresis (AGE) fol-
lowed by Southern blotting. HPV replication end products were analyzed using 
one-dimensional (1D) AGE, HPV replication intermediates were analyzed 
using two-dimensional (2D) neutral/neutral (N/N), 2D neutral/alkaline (N/A) 
and three-dimensional (3D) neutral/neutral/alkaline (N/N/A) AGE analysis. 2D 
and 3D AGE analyses are based on running consecutive perpendicular gel 
electrophoresis analyses under different electrophoresis conditions. 2D N/N 
AGE enables the separation of branched replication intermediates and linear 
molecules (231, 232), 2D N/A AGE facilitates the analysis of replication inter-
mediates based on their nascent strand composition (233), and 3D N/N/A AGE 
combines the 2D N/N and N/A analyses (234, 235). The experimental proce-
dures used during DNA extraction and analysis have been described in the 
Materials and Methods sections of papers I, II and III.   
U2OS cells are not natural papillomavirus host cells. The U2OS (originally 
2T) cell line was derived from a human mesenchymal tumor, specifically a 
moderately differentiated osteogenic sarcoma of the tibia from a 15-year-old 
patient (236). The cells are characterized by the preservation of mitotic activity 
(even in crowded cultures), an epithelial-like growth pattern, and extensive 
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chromosomal rearrangements (236). The U2OS cell line-based assay system 
cannot model the entire HPV life cycle culminating with the production of the 
viral particles; however, our data suggest the system is suitable to study HPV 
replication. The initiation of HPV replication in U2OS cells requires the 
expression of the full-length viral replication proteins E1 and E2, and later 
studies by our research group have demonstrated that the transcription patterns 
of the genomes of HPV types 18, 11 and 5 in U2OS cells are similar to those in 
keratinocytes (30, 31, 237). Additionally, the generation of oligomeric HPV 
genomes upon initial HPV replication was also observed in the SiHa, HeLa and 
C-33 A cells, and the HPV replication intermediates generated in U2OS cells 
were similar to the HPV replication intermediates observed during the initial 
amplification of HPV genomes in the HaCaT cells. The SiHa, HeLa and C-33 A 
cell lines were derived from cervical carcinomas (238–240), HaCaT cells were 
established from spontaneously transformed epithelial cells (241).  
AGE analysis enables the characterization of replication intermediates and 
end products based on the molecular weight and shape of the analyzed mole-
cules, and is not always sufficient to identify the analyzed molecules. For the 
characterization of oligomeric HPV genomes, restriction analyses and specific 
enzyme treatments were used prior to 1D AGE to alleviate the limitations of 
AGE analysis. During the characterization of HPV replication intermediates, 






5. RESULTS AND DISCUSSION 
5.1 Generation of oligomeric molecules  
of the viral genome during the replication  
of HPV genomes in U2OS cells (I) 
To study the replication of HPV genomes, our research group developed a 
U2OS cell line-based assay system that is capable of supporting the replication 
of high- and low-risk mucosal and cutaneous HPVs (I). The initial transient 
amplification of HPV was mimicked by transfecting the U2OS cells with plas-
mids containing HPV genomes (I, Fig. 1); the stable maintenance replication of 
HPV was mimicked by generating stable HPV-positive U2OS subclone cell lines 
(I, Fig. 2); and the vegetative amplification replication of HPV was achieved by 
cultivating stable HPV-positive cell lines under dense cell culture conditions (I, 
Fig. 3). The U2OS cell line supported the initial transient, stable maintenance and 
vegetative amplification replication phases of HPV low-risk mucosal types 6b 
and 11, high-risk mucosal types 16 and 18, and cutaneous types 5 and 8 (I, Fig. 1, 
Fig. 2, Fig. 3). The initiation of HPV replication in U2OS cells is dependent on 
the expression of the viral replication proteins E1 and E2, which can be derived 
either from the viral genome or exogenous expression vectors (I, Fig. 1e).  
We noticed that HPV genomic replication in U2OS cells not only yielded 
viral molecules containing a single copy of the HPV genome (hereafter referred 
to as monomeric HPV genomes) but also generated HPV genomes in a higher 
molecular weight form (I, Fig. 5a and b). An analysis of the HPV18 DNA 
extracted from transfected U2OS cells mimicking the initial transient repli-
cation phase of the viral genome revealed that the HPV DNA in the host cells 
was in a predominantly monomeric genomic form up to 4 days post-transfection 
(I, Fig. 5a, lanes 1–2 and 4–5), although higher molecular weight forms were 
also detected. At three weeks post-transfection, only the higher molecular 
weight forms were observed (I, Fig. 5a, lane 7), indicating a selective advantage 
for the maintenance of higher molecular weight forms during the stable mainte-
nance replication phase.  
The analysis of HPV18-positive U2OS subclone cell line #1.13 confirmed 
that the majority of HPV genomic material persists in U2OS cells in the higher 
molecular weight forms (I, Fig. 5b, lane 1). Under conditions mimicking the 
onset of vegetative amplification of the viral genome, robust amplification of 
both the monomeric and higher molecular weight HPV18 genomes occurred (I, 
Fig. 5b, lanes 2–6), demonstrating that both forms are replication competent. 
Restriction and 2D N/N AGE analyses revealed that the higher molecular 
weight forms of HPV18 DNA were episomal molecules containing several 
copies of the viral genome (hereafter referred to as oligomeric HPV genomes 
for brevity) (I, Fig. 5c, 5d, 5f, 5g and 5h).  
In addition to the U2OS cell line-based assay system, oligomeric papilloma-
virus genomes have also been detected in numerous tissue samples collected 
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from HPV-infected patients (127–129, 131–133), HPV-transformed human 
keratinocyte cell lines established from cervical lesions (125, 126), and BPV1-
positive mouse fibroblast cell line ID13 (115). Because an increased prevalence 
of oligomeric genomes was observed over time compared with the prevalence 
of monomeric genomes, the oligomeric genomes likely have a selective 
advantage over single-copy HPV genomes during prolonged maintenance in 
dividing cells. Thus, oligomerization is likely especially important for the stable 
maintenance phase of viral replication. The long-term maintenance of viral 
genomes depends on the replication and segregation functions of episomal 
molecules, and oligomeric HPV genomes can be expected to be efficient in both 
functions. During the replication of an oligomeric genome, a single initiation 
event would trigger the synthesis of several copies the HPV genome and ensure 
a high copy number of viral genomes in the host cell, even under circumstances 
when the expression of viral replication proteins is at a low level. Similarly, 
during the segregation of viral genomes between daughter cells, oligomeric 
molecules would have advantages over a large number of monomeric genomes.  
Several mechanisms could potentially lead to the generation of oligomeric 
HPV genomes. Additionally, oligomerization may be a separate process or it 
could be linked to other viral functions, with genomic replication an especially 
likely candidate. Moreover, although oligomeric HPV genomes have been 
detected both in vitro and in vivo and hold advantages over monomeric 
genomes during long-term maintenance in host cells, they may represent an 
aberrant form of the HPV genome because only monomeric viral genomes are 
ultimately packaged into viral particles. Therefore, if oligomeric HPV genomes 
are part of the productive viral life cycle, they must eventually be rearranged 
back into monomeric genomes.  
The generation of linear concatemeric molecules containing several copies 
of the viral genome has been described for bacteriophage SPP1 replication 
(chapter 2.3.3 Recombination-dependent DNA replication). The SPP1 dsDNA 
genome takes a circular form upon entering the host cell but is in linear form 
when packaged into viral particles. The linear concatemeric molecules gener-
ated during SPP1 replication through a switch from circle-to-circle theta repli-
cation to recombination-dependent rolling-circle replication serve as necessary 
substrates for the packaging machinery. The SPP1 rolling-circle mediated 
model for the generation of concatemeric viral genomes suggests that rolling-
circle replication may also be involved in the generation of HPV viral oligo-
mers. The involvement of rolling-circle replication in HPV vegetative amplifi-
cation replication has been previously proposed (117), lending further plausi-
bility to this particular hypothesis. However, there are inconsistencies between 
the oligomeric molecules generated during HPV initial amplification and SPP1 
replication. Oligomeric HPV genomes are circular molecules and not linear; 
however, HPV oligomers may become circular after these molecules have been 
generated as linear concatemers and this inconsistency does not exclude the 
possibility of similarities among the mechanisms used by these viruses to 
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generate oligomeric molecules. A more significant inconsistency between the 
HPV oligomerization model and the mechanisms utilized by SPP1 is related to 
the purpose of the generated oligomers because while SPP1 linear concatemers 
are required for viral packaging, the biological relevance of HPV oligomers 
remains unknown.  
 
 
5.2 HPV genomic oligomers form  
via homologous recombination during  
the initial amplification of the HPV genome (II) 
To investigate the generation of oligomeric HPV genomes, we focused on the 
initial transient amplification phase of HPV replication when the viral genomic 
oligomers first appear (II). As previously indicated, the initial transient 
replication was mimicked by transfecting U2OS cells with plasmids containing 
HPV genomes. To further evaluate the importance of oligomerization in the 
HPV replication cycle, two HPV types were used during the analysis: high-risk 
type 18 and low-risk type 11.  
First, we confirmed the results obtained in reference I Figure 5a and b (II, 
Fig. 1c) and again observed that when HPV18-transfected U2OS cells were 
cultivated for 2 weeks under subconfluent cell culture conditions with regular 
passaging, the initial prevalence of monomeric viral genomes at early time 
points (II, Fig. 1c, lanes 1–5) was replaced by the prevalence of oligomeric viral 
genomes at later time points (II, Fig. 1c, lanes 7–8). When the HPV18wt-
transfected cells were cultivated under dense cell culture conditions to induce 
the vegetative amplification of viral genomes, the oligomeric genomes became 
the prevalent form of HPV DNA, although the monomeric genomes also 
underwent amplification (II, Fig. 1c, lanes 11–12). These data confirmed that 
oligomeric HPV genomes are generated during the initial amplification phase of 
viral replication, and they appear to have a selective advantage over monomeric 
genomes during the stable maintenance phase and are replication competent 
during the vegetative amplification phase of replication.  
To further characterize the oligomeric molecules, LMW DNA from HPV18-
transfected U2OS cells was subjected to a restriction enzyme analysis (II, Fig. 
2a and b), topoisomerase I treatment (II, Fig. 2c) and 2D N/N AGE (II, Fig. 2e 
and 2f). These analyses confirmed that the HPV18 oligomers are episomal con-
catemers containing the viral genome in a head-to-tail orientation.  
After determining the characteristics of the oligomeric genomes, we 
evaluated the role of viral proteins in the induction of oligomerization (II, Fig. 
3b). Because oligomeric HPV genomes are generated during the initial amplifi-
cation replication, it is highly unlikely that either of the late viral proteins that 
are expressed during the late stages of viral replication is involved in the pro-
cess. Indeed, the subgenomic HPV18 construct that lacks the late open reading 
frames encoding viral capsid proteins L1 and L2 (the HPV18E construct) 
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demonstrated efficient replication and oligomerization (II, Fig. 5b, lanes 1–4), 
confirming that the L1 and L2 proteins are not necessary for oligomerization. 
To analyze the role of the HPV early proteins, a series of full-length HPV18 
mutant genomes were generated, and they each lacked the expression of a single 
early viral protein. The HPV18 E6¯ (II, Fig. 3b, lanes 4–6), E7¯ (II, Fig. 3b, 
lanes 7–9), E8¯ (II, Fig. 3b, lanes 13–15), E4¯ (II, Fig. 3b, lanes 19–21), E1E4¯ 
(II, Fig. 3b, lanes 22–24) and E5¯ (II, Fig. 3b, lanes 25–27) mutant genomes 
were all replication capable and produced oligomeric viral genomes, indicating 
that the expression of these viral proteins is not necessary for oligomerization.  
The HPV18 E1¯ (II, Fig. 3b, lanes 10–12) and E2¯ (II, Fig. 3b, lanes 16–18) 
mutant genomes were replication deficient as expected. To investigate the role 
of E1 and E2 proteins in the initiation of oligomerization, we co-transfected 
U2OS cells with a minicircle plasmid containing the non-coding region of the 
HPV18 genome (the HPV18 URR construct) and the E1 and E2 expression 
vectors (II, Fig. 4). The HPV18 URR construct contains the origin of HPV18 
replication and viral regulatory regions but does not express any viral proteins. 
Nonetheless, the HPV18 URR construct was capable of oligomerization as well 
as replication in the presence of the viral replication proteins E1 and E2 (II, Fig. 
4), raising the possibility that oligomerization is induced by replication. 
Whether the E1 and E2 protein have an additional function in the oligomeriza-
tion process separate from their functions as replication factors could not be 
determined during these experiments. Collectively, these data suggest that oli-
gomerization is linked to or the direct result of HPV genomic replication, and it 
requires no other viral factors than those associated with viral replication.  
The replication of circular molecules, such as the HPV genome, could lead 
to the generation of catenated molecules; however, the generation of circular 
concatemeric molecules cannot be directly linked to any of the replication 
mechanisms associated with the replication of circular molecules. Circular 
genomes can replicate either via theta or rolling-circle replication, and neither 
of these mechanisms is capable of generating the observed oligomeric HPV 
genomes. However, rolling circle replication can generate linear concatemeric 
molecules, which may then be circularized by the host cell. Alternatively, the 
generation of head-to-tail concatemeric molecules may be associated with 
recombination. Both rolling-circle replication and HR have previously been 
associated with papillomavirus replication (117, 141, 150).  
To elucidate the mechanism underlying the generation of HPV oligomeric 
molecules U2OS cells were co-transfected with two distinguishable HPV18 (II, 
Fig. 5) or HPV11 (II, Fig. 6) genomes. The HPV18wt genome was co-
transfected with the truncated HPV18E construct and produced HPV18 genomic 
oligomers containing both the HPV18wt and HPV18E molecules (II, Fig. 5b, 
lanes 5–8). The co-transfection of HPV11 E1¯ and E2¯ mutant genomes, which 
are incapable of replication independently, produced HPV11 genomic 
oligomers containing both the E1¯ and E2¯ mutant genomes (II, Fig. 6, lanes 
13–16). Rolling-circle replication uses a single molecule as a template for 
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generating multimers; however, HR occurs between two separate molecules. 
The generation of oligomeric molecules containing two different HPV genomes 
can only be achieved through HR, and these results indicate that HPV genomic 
replication is associated with cellular HR. However, these results do not rule out 
the possible involvement of rolling-circle replication in the initial amplification 
of the HPV genome. The concatemeric genomes of bacteriophage SPP1 are 
generated via recombination-dependent sigma type of rolling-circle replication. 
The first rounds of SPP1 replication proceed via unidirectional theta replication; 
however, it has been suggested that the progression of theta replication forks is 
quickly blocked, which leads to the collapse of these replication forks and gen-
erates DSBs (242, 243). The recombination-dependent re-initiation of repli-
cation subsequently triggers the onset of sigma replication and leads to the gen-
eration of concatemeric viral DNA (243). Thus, a mechanism that combines HR 
and rolling-circle replication may be involved in the generation of oligomeric 
HPV genomes.  
The presence of oligomeric HPV genomes in tissue samples collected from 
HPV-infected patients has been previously noted (127–129, 131–133); how-
ever, we also determined that several eukaryotic cell lines in addition to the 
U2OS cell line were capable of supporting the oligomerization of HPV18E8¯ 
mutant and HPV11wt genomes during the initial amplification phase of viral 
replication (II, Fig. 7). The oligomerization of HPV genomes was analyzed in 
the HPV16-positive SiHa (II, Fig. 7a and 7c, lanes 1–9), HPV18-positive HeLa 
(II, Fig. 7b and 7c, lanes 10–18) and HPV-negative C-33 A (II, Fig. 7d and e) 
cell lines, which were all derived from cervical carcinomas (238–240). The 
SiHa, HeLa and C-33 A cell lines all supported HPV genomic oligomerization 
as well as replication, although not as efficiently as the U2OS cell line, indi-
cating that HPV oligomeric genomes are generated in all cell lines capable of 
supporting HPV replication. We also initiated a collaboration with the 
Women’s Clinic of the University of Tartu Hospital and analyzed cervical brush 
or colposcopy samples collected from HPV-infected women with persistent 
HPV18 or HPV16 infections. We published the results from the analysis of 
three patient samples, and they all contained oligomeric HPV molecules (II, 
Fig. 8). Our data together with the data from previously published research 
papers demonstrate that oligomeric HPV genomes can be found in vivo, sug-
gesting that the oligomerization of HPV genomes is a naturally occurring phe-
nomenon.  
The efficient oligomerization of the HPV18 URR plasmid in the presence of 
E1 and E2 proteins suggests that oligomerization is replication-dependent. The 
co-transfection experiments with two distinguishable HPV18 or HPV11 
genomes clearly demonstrates the presence of HPV genomic oligomers gener-
ated through HR. Collectively, these data indicate the involvement of cellular 
HR in HPV replication.  
HR is involved in both ATM-mediated DSB repair and ATR-mediated repair 
of collapsed replication forks. The initial amplification replication of HPV 
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genomes is insensitive to the inhibition of the ATM-Chk2 pathway (203, 204); 
however, members of the ATR pathway (ATRIP and TopBP1) co-localize with 
HPV replication foci (204). TopBP1 is necessary for the establishment of HPV 
episomes in infected cells (110), and implicated in the ATR-mediated rescue of 
stalled replication forks in eukaryotic cells (111, 113). In eukaryotic cells, HR is 
facilitated by the MRN complex. The localization of MRN complex compo-
nents with regard to viral replication centers has not been analyzed during the 
initial amplification phase of HPV replication; however, members of the MRN 
complex are recruited to HPV replication centers during stable maintenance and 
vegetative amplification replication (142, 143). Importantly, efficient vegetative 
amplification relies on the recruitment of the MRN complex and the Rad51 
protein to HPV replication centers as well as the nuclease activity of Mre11 
(143). Collectively, these data demonstrate the necessary engagement of the 
homologous repair machinery during HPV replication and indicate that this 
engagement may be mediated by the ATR signaling pathway. Our results, how-
ever, demonstrate that HR end products are generated during HPV replication.  
The functions of cellular DDR and HR machinery activation during HPV 
replication remain unknown. The essential functions of the MRN complex in 
eukaryotic and prokaryotic cells may be the resolution of replication 
intermediates and the rescue of stalled replication forks (171, 188), and the 
MRN-mediated activation of the ATR signaling pathway has similarly been 
proposed as primarily facilitating the repair of stalled and collapsed replication 
forks (169, 185). During polyomavirus replication, the ATM and ATR signaling 
pathways are both activated by replication stress (222, 224), and cellular DDR 
activation is required for the maintenance of viral replication fork integrity 
(224, 229). Thus, the involvement of HR in HPV genomic replication may be 
limited to similar functions.  
During bacteriophage SPP1 replication, the induced collapse of replication 
forks facilitates a shift to a recombination-dependent mode of replication. The 
involvement of a second replication mechanism has long been suspected in 
papillomavirus replication, especially during the later phases of viral replication 
(117), and the engagement of HR during viral replication may indicate the pres-
ence of a recombination-dependent mode of HPV replication (150). During 
bacteriophage SPP1 replication, the initiation of recombination-dependent mode 
of replication is facilitated by a viral recombination protein (243); however, 
with the possible exception of the HPV replication proteins E1 and E2, viral 
proteins are dispensable for the recombination-dependent generation of HPV 
oligomers (II, Fig. 3b and 4) and recombination-associated functions have not 
been indicated for any HPV proteins. The HPV genome is also significantly 
smaller than the SPP1 genome and heavily reliant on host factors for the repli-
cation of its genome. Therefore, while HPV may, similarly to SPP1, switch to a 
recombination-dependent mode of replication, the mechanisms these viruses 




5.3 Evidence of the involvement  
of two different replication mechanisms  
in the initial amplification of the HPV genome (III) 
The initial amplification of the HPV genome is dependent on the presence of 
the viral E1 and E2 proteins ((83); I, Fig. 1e; II, Fig. 3), and it is believed to 
proceed via bidirectional theta replication; however, initial amplification also 
produces oligomeric HPV genomes generated via HR (II), and the components 
of the ATR signaling pathway are recruited to HPV replication foci during this 
phase (204). To determine the mechanism underlying the initial amplification of 
the HPV genome, replication intermediates generated in HPV18-transfected 
U2OS cells were analyzed using 2D N/N, 2D N/A and 3D N/N/A AGE analysis.  
An analysis of the replication intermediates generated during the initial 
amplification of the HPV18 genome in U2OS cells indicated that the initial 
rounds of HPV replication proceed via bidirectional theta replication initiated 
from the origin of replication located in the non-coding region of the HPV18 
genome (the URR origin) (III, Fig. 2). Theta replication intermediates retained 
their strong presence throughout the analyzed time points up to 5 days post-
transfection (III, Fig. 2). We noticed a considerable accumulation of late theta 
replication intermediates, which indicated difficulties with the completion of 
theta replication (III, Fig. 2, Fig. 3, and Fig. 4).  
We also noted the presence of replication intermediates that do not resemble 
the intermediates of bidirectional theta replication (III, Fig. 2, Fig. 3, Fig. 4, Fig. 
5, and Fig. 6). These novel or secondary replication intermediates were not ini-
tiated from a specific origin sequence (III, Fig. 3a and Fig. 5) and contained a 
unidirectional replication fork (III, Fig. 4 and Fig. 5). The unidirectional novel 
replication forks did not have a fixed polarity because these forks can run 
through the HPV genome in either direction (III, Fig. 6). Because the char-
acteristics of the novel replication intermediates indicated essential differences 
with the intermediates of bidirectional theta replication, we concluded that a 
second mechanism was involved in the initial amplification of the HPV18 
genome. Notably, we were unable to detect molecules representing the very early 
intermediates of the second replication mechanism because the observed inter-
mediates of the second replication mechanism never emanated from the signal 
representing 1n linear non-replicating molecules (III, Fig. 2, Fig. 3, and Fig. 5). 
This result may indicate that the very early intermediates of the second repli-
cation mechanism are especially labile molecules. Alternatively, the structures 
generated following the initiation of the second replication mechanism may 
simply be larger and more structurally complex than the 1n linear molecules.  
Both bidirectional theta and second replication intermediates were observed 
during the initial amplification of HPV18 genomes in the HaCaT cells (III, Fig. 
7). The HaCaT cell line was established from spontaneously transformed epi-
thelial cells and retains the ability to differentiate distinctive to normal keratino-
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cytes (241). The generation of similar replication intermediates in both U2OS 
and HaCaT cells indicates that the replication intermediates observed during the 
HPV18 genome replication in U2OS cells represent authentic HPV replication 
intermediates.  
Importantly, the analysis of uncut HPV18 replication intermediates was used 
to investigate the involvement of rolling-circle replication in the initial amplifi-
cation of the HPV genome (III, Fig. 1c). Rolling-circle replication produces 
distinct σ-shaped replication intermediates, and these intermediates were not 
observed during the analysis of uncut HPV18 replication intermediates (III, 
Fig. 1c), indicating that rolling-circle replication is not involved in HPV 
replication.  
Bidirectional theta replication has long been considered to be the mechanism 
underlying the stable maintenance replication of papillomavirus genomes (114, 
115, 117), and it has also been implicated in the vegetative amplification of the 
HPV genome (116). Our data confirmed the involvement of bidirectional theta 
replication in the initial amplification replication of HPV genomes. Because the 
bidirectional theta replication intermediates appeared before the second repli-
cation intermediates and were likely initiated from the HPV18 URR origin (35), 
bidirectional theta replication is likely the mechanism underlying the E1/E2-
dependent viral replication.  
An analysis of replication intermediates alone is not sufficient to identify the 
mechanism underlying the generation of the second non-theta group of repli-
cation intermediates. However, because of the strong evidence for the involve-
ment of HR in HPV genomic replication observed by our group and other 
research groups, RDR is a likely candidate for the mechanism underlying the 
generation of the second replication intermediates.  
The characteristics of the intermediates of the second replication mechanism 
noted here are consistent with RDR. RDR is initiated by the invasion of a 
ssDNA 3’ end into a homologous sequence, and then either a fully functional 
replication fork is assembled and semiconservative replication is established or 
conservative migrating bubble replication is established (192–196). RDR does 
not require a specific viral sequence for initiation because the site of replication 
initiation is determined by the sequence of the invading ssDNA end. The initia-
tion structures of RDR are larger than the 8 kbp HPV genome, and based on 
analogy with the branch migration of Holliday junctions, the strand invasion 
intermediates would also be quite labile molecules (244), thus accounting for our 
inability to detect the initiation structures of the second replication mechanism.  
The origin of the free 3’ ssDNA ends and the trigger of the second repli-
cation mechanism are unknown. During the recombination-dependent rolling-
circle replication of bacteriophage SPP1 genomes, RDR is likely initiated from 
a collapsed theta replication fork (243). An analysis of uncut HPV18 replication 
intermediates indicates that σ-shaped intermediates characteristic of rolling-
circle replication are not present during the initial amplification of the HPV 
genome, thus ruling out the presence of a replication mechanism similar to that 
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of SPP1. However, the initiation of the papillomavirus second replication 
mechanism may result from a similar event.  
The E1 protein is the sole component of the HPV hexameric helicase and 
has the intrinsic ability to generate DSBs in the viral genome (204, 205). 
However, the E1-mediated generation of DSBs occurs during the 
overexpression of the E1 protein, and large-scale DNA damage has not been 
observed during E1/E2-dependent viral replication (203, 204). However, there 
are still indications that the E1/E2-dependent bidirectional theta replication of 
HPV genomes may generate replication-associated DSBs leading to the 
initiation of a recombination-dependent mode of replication. For example, the 
E2-mediated recruitment of TopBP1 is required for productive HPV replication 
(110) and TopBP1 co-localizes with HPV replication foci during the initial 
amplification phase of replication (204). TopBP1 is associated with the ATR-
mediated rescue of stalled replication forks (111, 113). The TopBP1-mediated 
rescue of stalled replication forks relies on the presence of the MRN complex 
and the nuclease activity of Mre11 (169), both of which are also necessary for 
the efficient replication of HPV genomes during the vegetative amplification 
phase (143).  
It remains unclear whether triggering the second replication mechanism is a 
one-off event, meaning that once it is triggered, the second replication 
mechanism can continuously re-initiate without the need for further triggering 
events, or whether the second replication mechanism must be continuously 
induced. During SPP1 replication, once recombination-dependent rolling-circle 
replication is initiated, the process takes over the replication of the viral 
genome. During HPV replication, however, bidirectional theta replication 
intermediates occur at later time points simultaneously with the intermediates of 
the second replication mechanism, indicating a certain degree of flexibility in 
the choice of mechanism for HPV genome replication.  
The accumulation of nearly fully replicated late theta intermediates may also 
be involved in inducing the second replication mechanism. This phenomenon is 
not novel because the accumulation of nearly full replicated late theta inter-
mediates is also noted during polyomavirus replication. In the case of the 
polyomavirus SV40, replication forks initiated at the origin of replication and 
proceeding bidirectionally halted when replication was approximately 91% 
complete (219–221); the halting of replication forks likely occurred in prepa-
ration for the separation of daughter molecules. The separation of nearly fully 
replicated intermediates generates molecules containing either regions of 
ssDNA or even DSBs and potentially leads to the activation of RDR.  
Based on the analysis of replication intermediates that are generated during 
the initial replication of the HPV18 genome in U2OS cells, we propose a dual-




5.3.1 Dual-mechanism model of papillomavirus replication 
The initiation of HPV replication is dependent on the presence of E1 and E2 
proteins and the origin of replication located in the non-coding region of the 
viral genome (the URR origin) (I, Fig. 1e; II, Fig. 3; (34, 37, 82–86)), and the 
initial HPV replication proceeds via bidirectional theta structures (III, Fig. 2). 
After the onset of E1/E2-dependent bidirectional theta replication, the second 
replication mechanism is initiated (III, Fig. 2) as a direct result of the ongoing 
E1/E2-dependent replication. The second replication mechanism is likely RDR 
(II, Fig. 5 and 6; (142, 143, 150, 204)). A possible trigger for the initiation of 
the second replication mechanism may be the stalling and eventual collapse of 
the theta replication forks, which results in the recruitment of cellular DDR 
factors to viral replication foci and the re-initiation of replication via a 
recombination-dependent mechanism. Alternatively, the recruitment of cellular 
DDR factors to viral replication centers may be facilitated by viral proteins 
involved in HPV replication similarly to the recruitment of cellular replication 
machinery to the viral origin of replication, and the process may proceed 
without requiring a specific triggering event. Throughout papillomavirus 
infection, however, the viral genome retains the availability of both E1/E2-
mediated and recombination-dependent initiation of replication.  
There are several indications that HPV genomes are inherently capable of 
replicating via two different mechanisms during the stable maintenance and 
vegetative amplification phases of replication.  
The analysis of stable maintenance replication in HPV-positive cell lines 
derived from naturally infected cervical tissues demonstrated that HPV 
genomes replicate via two different modes, once-per-S-phase (similar to cellular 
DNA) or randomly, and the selected mode is determined by the availability of 
viral replication proteins (124). The presence of the E1 protein, however, is not 
required for the stable maintenance replication phase (84). However, during 
stable maintenance replication, bidirectional theta replication intermediates 
initiated from the E1/E2-dependent URR origin of replication are the prevalent 
replication intermediates (117), indicating that E1/E2-dependent bidirectional 
theta replication is involved during this phase of HPV replication. Similarly, 
proteins involved in cellular DDR and HR co-localize with HPV replication 
foci in approximately 50% of HPV-positive cells during the stable maintenance 
phase of replication (142, 143), although the inhibition of cellular DDR has no 
discernible effect on stable maintenance replication (141, 143).  
The vegetative amplification of the HPV genome is dependent on the 
presence of the E1 protein (84). An analysis of the replication intermediates 
generated during the vegetative amplification of HPV types 16 and 31b, how-
ever, indicated that the most prevalent replication intermediates were generated 
via a unidirectional replication mechanism without specific initiation or termi-
nation sequences rather than bidirectional theta replication initiated from the 
E1/E2-dependent URR origin of replication (117). Cellular DDR activation 
contributes to vegetative amplification by activating caspases involved in the 
47 
cleavage of the E1 protein, which is required for efficient vegetative 
amplification of the HPV genomes (140, 141). However, whether E1 protein 
cleavage contributes to generating the unidirectional replication mechanism 
remains unknown. Additionally, the co-localization of HPV replication foci and 
proteins associated with cellular DDR and HR increases after the onset of the 
vegetative amplification of the HPV genome (141–143), and HPV vegetative 
amplification replication is notably decreased but not eliminated by disrupting 
the nuclease activity of Mre11 and the localization of the MRN complex and 
Rad51 protein to the HPV replication foci (143).  
These data indicate that both E1/E2-dependent replication and a second, 
likely recombination-dependent, replication mechanism are simultaneously 
utilized for the replication of HPV genomes during the stable maintenance and 
vegetative amplification phases of viral replication. The analysis of the repli-
cation intermediates generated during the initial amplification phase of the 
HPV18 genome also indicated the involvement of two separate mechanisms 
during that phase of HPV replication. Collectively, these data suggest that 
papillomaviruses are capable of using two different replication mechanisms to 
multiply the viral genome throughout all three phases of HPV replication.  
 
5.3.2 Perspectives on the dual-mechanism model of replication 
The results presented in this thesis highlight the unique characteristics of the 
mechanism underlying HPV genomic replication. The utilization of several 
different mechanisms during the viral replication cycle is not uncommon, and 
the engagement of factors involved in cellular recombination and repair func-
tions for the replication of the viral genome is not unusual. However, HPV rep-
lication obviously does not follow any of the previously described models for 
other DNA viruses (e.g., polyomavirus SV40 or bacteriophage SPP1 repli-
cation). The uniqueness of the HPV replication mechanism likely mirrors the 
uniqueness and complexity of the papillomavirus life cycle. 
Additional work must be performed to identify with a degree of certainty the 
second mechanism involved in the initial amplification replication of the HPV 
genome. Because we propose that the second replication mechanism is 
recombination-dependent, different cellular repair and recombination factors 
should be knocked out and the associated effects on the intermediates of the 
second replication mechanism should be investigated. Additionally, the structure 
of the replication intermediates generated via the second replication mechanism 
should be further characterized using direct visualization via electron microscopy 
or atomic force microscopy. After identifying the replication mechanism, a 
detailed investigation of the events occurring during the initiation, elongation and 
termination phases of the second replication mechanism should be conducted.  
Utilizing two different replication mechanisms would enable papilloma-
viruses to maintain HPV genomic replication under changing host cell envi-
ronments, and such a construct would contribute to highly efficient replication 
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during the amplification phases. The exact mechanism underlying the second 
mode of replication remains unknown, although evidence suggests that the ini-
tiation of the second mechanism is not licensed by the (exact) same factors 
involved in the initiation of the bidirectional theta replication of HPV genomes. 
The presence of two replication mechanisms with different initiation require-
ments certainly offers a degree of flexibility for host cell conditions that are 
conducive to HPV replication. If the second replication mechanism is indeed 
largely driven by cellular repair and recombination machinery, it would provide 
a mechanism of replicating the viral genome that requires minimal viral repli-
cation factors (with the onset of the second replication mechanism being a 
likely exception). Such a mechanism would allow viral replication to occur 
even under host cell conditions that do not permit the large-scale expression of 
viral proteins, which would make the second replication mechanism especially 
important during the stable maintenance phase of replication when the expres-
sion of proteins from the HPV genome is low. Because of the apparent ability 
of the second replication mechanism to function simultaneously with bidirec-
tional theta replication without generating aberrant replication intermediates, 
this mechanism would also be conducive to HPV replication during the initial 
and vegetative amplification phases. Therefore, a dual-mechanism replication 
model would be highly beneficial for the virus. 
Demonstrating the presence of two different replication mechanisms during 
papillomavirus replication could have significant implications for the treatment 
of HPV-associated lesions. Specific inhibitors of HPV replication are not cur-
rently used for the treatment of HPV-associated afflictions; however, the 
involvement of two different mechanisms in the replication of the HPV genome 
indicates that any potential drug should be able to target both of these mecha-
nisms to eradicate HPV infection. It is highly unlikely that a single inhibitor 
could be efficient against two mechanisms that display such considerable dif-
ferences while maintaining the specificity required to only affect viral DNA 
replication. Thus, a combination of inhibitors should most likely be used, with 
one inhibitor that targets E1/E2-dependent replication via bidirectional theta 
structures and one inhibitor that targets the second replication mechanism. The 
dual-mechanism model of replication would also provide a reason to re-
examine any potential drugs that were designed to inhibit conventional E1/E2-
dependent papillomavirus replication but failed to eliminate viral replication. 
These drugs may have been functional against their intended targets, although 
the presence of the second replication mechanism could have resulted in the 
overall continuation of viral replication. Additionally, if the second replication 
mechanism is indeed RDR, drugs originally intended for the treatment of other 
diseases (e.g., anti-cancer drugs) might be repurposed for the treatment of papil-
lomavirus infections in combination with inhibitors of E1/E2-dependent repli-




1)  The U2OS cell line-based assay system developed by our research group is 
suitable for the analysis of genomic replication of both high-risk and low-
risk HPV types. 
 
2)  HPV initial amplification replication generates monomeric and oligomeric 
viral genomes. Although the monomeric genomes are initially the prevalent 
form of viral DNA, oligomeric forms appear to have a selective advantage 
during the long-term maintenance of HPV genomes in host cells.  
 
3)  Oligomeric HPV genomes are generated via HR, and the process is likely 
replication dependent. The generation of oligomeric viral genomes is a 
direct evidence of the actual engagement of cellular HR machinery during 
the replication of HPV genomes. 
 
4)  The replication intermediates generated during the initial amplification of 
the HPV18 genome were analyzed, and the results demonstrate that two 
separate mechanisms are involved in papillomavirus replication. One of the 
mechanisms is bidirectional theta replication, and we propose that the other 
mechanism is RDR. 
 
5)  We propose a dual-mechanism replication model for the replication of pap-











SUMMARY IN ESTONIAN 
Inimese papilloomiviiruse genoomi paljundamise  
varajaste etappide uurimine 
Inimese papilloomiviirused (HPVd) nakatavad inimorganismis teadaolevalt 
ainult ühte tüüpi rakke, naha ja limaskestade epiteelkoes paiknevaid kera-
tinotsüüte. Tavaliselt ei tekita HPV nakkus epiteelkoes märgatavaid haigus-
tunnuseid, kuid viiruse osadele variantidele ehk tüüpidele on omane võime kut-
suda esile peremeesrakkude ebatavaliselt kiiret paljunemist, mis võib viia 
nakatunud koes healoomuliste kasvajate arenguni. Pikaajaline HPV nakkus võib 
aga põhjustada viiruse tekitatud healoomulise kasvaja muutumise halvaloomu-
liseks. Püsivat HPV nakkust peetakse emakakaelavähi tekke kõige olulisemaks 
riskifaktoriks, kuid HPVd on seotud ka teiste genitaal- ja anaalpiirkonna ning 
pea- ja kaelapiirkonna kasvajate arenguga. 
Iga eduka viirusnakkuse käigus toimub nakatunud rakkudes lõpuks viiruse 
päriliku materjali (ehk viiruse genoomi) paljundamine ning uute viirusosakeste 
tootmine. HPV pärilikkusmaterjaliks on kaheahelaline DNA, mis võimaldab 
viirusel kasutada oma genoomi paljundamiseks peamiselt peremeesraku DNA 
paljundamise (ehk replikatsiooni) masinavärki. HPV päriliku materjali pal-
jundamise algatamisel ning peremeesraku replikatsiooni masinavärgi kaasa-
misel viiruse genoomi paljundamisesse mängivad aga võtmerolli kaks viirusliku 
päritoluga valku.  
HPV peremeesrakke keratinotsüüte iseloomustab keeruline, ettemääratud 
rakusurmaga lõppev elutsükkel, mille käigus rakud kaotavad paljunemisvõime 
ning sünteesivad endale ümber tugeva sarvkesta. Eduka HPV nakkuse korral 
siseneb viirus keratinotsüüti peremeesraku elutsükli varajases etapis, kuid uute 
viirusosakeste tootmine toimub alles elutsükli viimaseid etappe läbivates pere-
meesraku jäänukites. Seega peab HPV nakkuse käigus suutma end säilitada 
ning oma pärilikku materjali paljundada pidevalt muutuvas keskkonnas. Ilmselt 
tulenevalt vajadusest kohaneda peremeesraku keerulise elutsükliga toimub HPV 
genoomi paljundamine peremeesrakus kolmes selgelt eristuvas etapis: varajane 
kiire viiruse genoomi koopiaarvu tõus, genoomi koopiaarvu stabiilne säilita-
mine ja hiline kiire viiruse genoomi koopiaarvu tõus.  
Laboritingimustes on HPV peremeesrakkude kasvatamine ning nende elu-
tsükli matkimine küllaltki keeruline ning äärmiselt kulukas. Lisaks ei või-
maldanud kasutusel olnud metoodikad uurida HPV genoomi replikatsiooni 
varajasi etappe. Seetõttu ei ole HPV genoomi paljundamise täpne mehhanism 
ning protsessis osalevad rakulised faktorid veel täielikult teada, kuigi need tead-
mised on väga olulised HPV-vastaste ravimite väljatöötamiseks. HPV-ga naka-
tumise vältimiseks on välja töötatud mitmeid efektiivseid, kuid ainult väikese 
hulga HPV tüüpide vastu kaitset pakkuvaid vaktsiine, samuti on HPV tekitatud 
kasvajaid võimalik eemaldada erinevate meditsiiniliste protseduuridega. Siiski 
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ei ole praegu kasutusel mitte ühtegi ravimit, mis suudaks takistada viiruse 
paljunemist nakatunud koes.  
Käeolevas doktoritöös kajastatud uurimisprojekti eesmärk oli luua mudel-
süsteem, mida saaks rakendada HPV päriliku materjali paljundamise uuri-
miseks, ning rakendada loodud mudelsüsteemi viiruse replikatsiooni varajaste 
etappide uurimiseks.  
Välja töötatud mudelsüsteem põhineb HPV päriliku materjali sisestamisel 
inimese sääreluu kasvajast algatatud U2OS rakkudesse. Kuigi U2OS rakud ei 
ole HPV looduslikud peremeesrakud, suudavad nad toetada HPV genoomide 
kõiki kolme replikatsiooni etappi. U2OS rakkudel põhinevat mudelsüsteemi 
rakendades uurisime HPV päriliku materjali paljundamise varajases etapis 
tekkivaid viiruse DNA molekule, mis sisaldavad mitut viiruse genoomi koopiat. 
Selliste eripäraste HPV genoomide (edaspidi nimetatud viiruse või HPV ge-
noomi oligomeerideks) teket on varasemalt täheldatud nii püsivat HPV nakkust 
kandvatelt patsientidelt eraldatud koeproovides kui ka patsientidelt võetud 
koeproovidest algatatud HPV genoomi kandvate rakuliinide analüüsil. Me te-
gime kindlaks, et HPV genoomi oligomeeride teke on seotud viiruse genoomi 
paljundamisega ning toimub homoloogilise rekombinatsiooni kaudu. Homo-
loogiline rekombinatsioon osaleb inimese rakkudes mitmetes protsessides, kuid 
tavapäraselt rakendatakse seda rakus tekkinud DNA kahjustuste parandamisel. 
Päriliku materjali terviklikkuse säilitamine ja selle kahjustada saamise vältimine 
on rakkudele väga oluline, mistõttu inimese rakkudes on arenenud mitmed kee-
rukad mehhanismid DNA kahjustuste avastamiseks ning parandamiseks. Juba 
varem on HPV uurimise käigus täheldatud, et viiruse nakkuse käigus akti-
veeruvad peremeesrakus signaalid, mis algupäraselt peaksid tähistama rakulise 
DNA kahjustuste olemasolu. Nende signaalide olemasolu on teadaolevalt vaja-
lik viiruse päriliku materjali efektiivseks paljundamiseks, samuti on kirjeldatud 
DNA kahjustuste parandamiseks vajalike rakuliste valkude värbamine komp-
leksidesse, mis paljundavad HPV genoomi. Kuid meie rühmal õnnestus esma-
kordselt näidata, et rakulised DNA parandamise mehhanismid on reaalselt 
kaasatud HPV päriliku materjali paljundamisesse.  
Lisaks analüüsisime HPV molekule, mis tekivad viiruse päriliku materjali pal-
jundamise varajaste etappide käigus HPV replikatsiooni vahesaadustena. Uurides 
molekule, mis tekivad paljunemise protsessi käigus, on võimalik saada andmeid 
HPV genoomi replikatsiooni taga oleva mehhanism kohta. Meie tulemused näita-
sid, et viirus kasutab oma päriliku materjali paljundamiseks kahte eraldiseisvat 
mehhanismi. Üks neist, väga iseloomulike replikatsiooni vahesaadustega kahe-
suunalise theta replikatsiooni nime kandev mehhanism, on varasemalt seostatud 
HPV genoomi paljundamise hiliste etappidega. Kuid meie töö käigus ilmnesid ka 
uudsed, varem kirjeldamata replikatsiooni vahesaadused, mille tekkimise mehha-
nismi ei olnud võimalik kasutatud analüüsi käigus lõplikult selgitada. Tuginedes 
meie uurimisrühma ja teiste uurimisrühmade poolt avaldatud andmetele, pakume 
teise replikatsiooni mehhanismina välja rakuliste DNA parandamise mehha-
nismidega seotud rekombinatsioonist sõltuva replikatsiooni.  
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Me tõstatame hüpoteesi, et HPV on võimeline kõigi kolme replikatsiooni 
etapi jooksul kasutama kahte erinevat mehhanismi oma genoomi paljunda-
miseks. Viirusele oleks kahe eraldiseisva mehhanismi rakendamine oma päri-
liku materjali paljundamiseks äärmiselt kasulik, kuna kahe erineva mehhanismi 
kasutamine võimaldab viiruse genoomi paljundada erinevate peremeesraku 
tingimuste juures, mis on keratinotsüütide elutsükli iseärasustest tingituna HPV 
jaoks väga oluline. Samas võimaldab kahe mehhanismi üheaegne kasutamine 
paljundada viiruse pärilikku materjali lühikese aja jooksul äärmiselt efektiivselt. 
Samas raskendab kahe mehhanismi kasutamine viiruse DNA paljundamiseks 
oluliselt HPV genoomi replikatsiooni takistavate ravimite väljatöötamist, kuna 
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